Home » Newsletters » BioWorld Science

BioWorld Science

April 16, 2014

View Archived Issues

Lundbeck characterizes novel brain-penetrant PDE2A inhibitor

Molecular Templates presents novel therapeutic candidate for multiple myeloma

Janssen presents novel FASN inhibitors for the treatment of cancer

AQP-5 expression and polymorphisms predict early breast cancer survival

Germline PIGA mutations linked to new genetic syndrome

Ace2 gene therapy reduces liver fibrosis in mice

Evotec presents novel FGFR-3 inhibitors

New series of ERK 2 inhibitors patented by Novartis

Sanofi patents new apelin receptor modulators

Pfizer discloses novel BACE inhibitors

Akebia Therapeutics completes enrollment in a phase IIb study of AKB-6548

IRM designs novel GPR119 receptor modulators

Mucosis enters into collaboration and license agreement with Changchun

Pivotal phase III study of veliparib begins in non-small cell lung cancer

Akron Biotech receives NIH grant for method to isolate stem cells

TT-genotype of IL-23R has protective effect in lung transplant recipients

Akros Pharma begins phase I study of JTT-251 in diabetes

Novel putative antisense mitochondrial RNA-based therapy for renal cell carcinoma

Cellmid signs MK Tribody agreement with Biotecnol

Dynavax initiates phase III trial to expand safety database for HBV vaccine

PanOptica completes financing round and starts dosing in phase I trial of anti-VEGF eye drop

FDA approves GSK's albiglutide BLA for type 2 diabetes

Kineta RLB joint venture formed to develop drugs for autoimmune disease

Wilson Therapeutics raises funding for development of Wilson's disease therapy

FDA approves trade name for Medac's subcutaneous methotrexate

BioAlliance and TopoTarget to merge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...